Antiviral Therapy · 2013 · 26 citations · 11 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMolecular VirologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyHiv EpidemiologyResistance EpidemiologyCo-receptor UsageGenotypic Resistance TestingHiv Drug Resistance EpidemiologyNon-nucleoside InhibitorsNon-nucleoside Reverse Transcriptase InhibitorsNucleoside Reverse Transcriptase InhibitorsProtease Inhibitor ResistanceReverse Transcriptase Inhibitor Resistance
BACKGROUND: Drug resistance testing and co-receptor tropism determination are key components of the management of antiretroviral therapy for HIV-1-infected individuals. The purpose of this study was to examine trends of HIV-1 resistance and viral evolution in the past decade by surveying a large commercial patient testing database. METHODS: Temporal trends of drug resistance, viral fitness and co-receptor usage among samples submitted for routine phenotypic and genotypic resistance testing to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), as well as for tropism determination were investigated. RESULTS: Within 62,397 resistant viruses reported from 2003 to 2012, we observed a decreasing trend in the prevalence of three-class resistance (from 25% to 9%) driven by decreased resistance to PIs (43% to 21%) and NRTIs (79% to 57%), while observing a slight increase in NNRTI resistance (68% to 75%). The prevalence of CXCR4-mediated entry among tropism testing samples (n=52,945) declined over time from 47% in 2007 to 40% in 2012. A higher proportion of CXCR4-tropic viruses was observed within samples with three-class resistance (50%) compared with the group with no resistance (36%). CONCLUSIONS: Decreased prevalence of three-class resistance and increased prevalence of one-class resistance was observed within samples reported between 2003 and 2012. The fraction of CXCR4-tropic viruses has decreased over time; however, CXCR4 usage was more prevalent among multi-class-resistant samples, which may be due to the more advanced disease stage of treatment-experienced patients. These trends have important implications for clinical practice and future drug discovery and development.
11
Antiretroviral Treatment of Adult HIV Infection
Scott M. Hammer, Joseph J. Eron, Peter Reiss et al. · JAMA · 2008 · 1K citations
Antiretroviral Treatment of Adult HIV Infection
Melanie Thompson, Judith A. Aberg, Pedro Cahn et al. · JAMA · 2010 · 725 citations